Novartis ‘biosimilar’ drug blocked by U.S. appeals court

A U.S. appeals court has blocked the sale of Novartis AG’s recently approved “biosimilar” form of Neupogen, the blockbuster Amgen Inc drug used to prevent infections in cancer patients. A lower court judge rejected Amgen’s request for an injunction. The U.S. Court of Appeals for the Federal Circuit ruled on Tuesday, however, that the injunction could take effect while Amgen’s appeal is pending.
Go to Source